Solidus Investment

Founded in 2017, Dr.Diary is a South Korean company specializing in diabetes management solutions. Its flagship application helps users monitor blood sugar levels, track exercise routines and food intake, receive personalized health insights, and communicate with healthcare professionals.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

Novelty Nobility is a biotechnology company specializing in the research and development of antibody-based therapeutics targeting novel angiogenesis factors. The company focuses on ophthalmology and oncology, aiming to address unmet medical needs through innovative treatments.

Founded in 2016, Neurophet is a neuroscience company based in Seoul, South Korea. It specializes in developing advanced brain stimulation simulation software, Neurophet tES Lab, and neuro-navigation technology to aid clinicians in treating patients with brain diseases.

Optolane Technologies Inc. is a biotechnology company based in Seongnam, South Korea, founded in 2012. The company specializes in manufacturing portable photo sensor chip-based PCR machines for life science applications. It has developed a diagnostic platform that offers molecular and immunoassay point-of-care testing alternatives. Optolane's semiconductor-integrated in-vitro diagnostic devices focus on real-time and digital PCR, utilizing advanced optical and thermal control systems. By providing innovative diagnostic solutions, Optolane aims to facilitate disease diagnosis and enhance the quality of life for individuals.

Himedi, Inc. is a digital health platform based in Seoul, South Korea, that facilitates connections between international patients and medical service providers. Founded in 2011, the company offers a hospital reservation service and provides consultations with doctors, ensuring that patients receive personalized recommendations for clinics. Service managers accompany clients throughout their medical journey, enhancing the overall experience for medical tourists. Himedi aims to improve the quality of life for its users by offering comprehensive support during their treatment processes.

Orum Therapeutics is a biotechnology company developing therapeutic antibodies using its proprietary cell-penetrating antibody platform. This platform targets specific intracellular proteins for treating genetic diseases and cancer, adapting to different cell types without chemical modifications.

Orum Therapeutics is a biotechnology company developing therapeutic antibodies using its proprietary cell-penetrating antibody platform. This platform targets specific intracellular proteins for treating genetic diseases and cancer, adapting to different cell types without chemical modifications.

Vitrosys Inc. is a bio-engineering company based in Yeongju, South Korea, founded in 2002. The company specializes in the development and manufacturing of plant-based medicines, utilizing advanced biotechnological methods to create products from single cells and tissues. Vitrosys offers a diverse range of health-related products, including natural materials, bio reactors, and functional foods designed to promote health. Its product line features cultured roots of Korean mountain ginseng and various extracts, vials, and beverages derived from these roots. Additionally, Vitrosys provides research outsourcing and joint research services, aimed at supporting the industrialization of beneficial plant resources in strictly controlled facilities. The company's commitment to biopharmaceutical innovation enables the extraction and identification of natural metabolites with physiological benefits for human health.

Alteogen Inc. is a biotechnology company founded in 2008 and headquartered in Daejeon, South Korea. The company specializes in the development of next-generation biopharmaceuticals, including long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. Alteogen's innovative technologies include NexP Fusion Technology for long-acting biobetters and NexMab ADC Technology for antibody-drug conjugates. Its current pipeline features several candidates in various stages of clinical trials, such as ALT-P1, a long-acting human growth hormone in Phase IIa, and ALT-Q2, a long-acting coagulation factor VII for hemophilia. Additionally, the company is developing ALT-P7 for targeted breast and gastric cancer and ALT-Q5, an antibody-drug conjugate for ovarian cancer. Alteogen also collaborates with other pharmaceutical companies, including Kissei Pharmaceutical and Cristalia, to enhance its product offerings.

Novarex Co., Ltd., founded in 2008 and headquartered in Cheongju, South Korea, specializes in the development and production of health functional foods and raw materials. The company offers a diverse range of dietary supplements, including lactic acid bacteria, probiotics, omega-3 products, and vitamins and minerals. Novarex provides various formulations such as tablets, hard capsules, powders, gummy jellies, and stick jellies, catering to different health needs, including eye health, dietary management, and support for pregnant women and children. Formerly known as Health Science Co., Ltd., Novarex rebranded in November 2011 to reflect its commitment to health and nutrition on both domestic and international markets.

BioLeaders Corporation is a healthcare company based in Yongin, South Korea, founded in 1999. The company focuses on developing innovative medicines, particularly in the field of oncology, with its flagship product being P53, an anti-cancer drug. BioLeaders is advancing several pipeline products, including BLS-H01, currently in phase 3 clinical trials for cervical cancer, and BLS-M07, which has completed phase 2b trials for the same condition. Additionally, the company is working on BLS-M22 for the treatment of Duchenne muscular dystrophy and BLC-H03, a vaccine adjuvant. Beyond pharmaceuticals, BioLeaders also offers health functional foods, raw materials, and functional cosmetic ingredients, positioning itself as a comprehensive provider in the healthcare sector.

Maniker F&G Co., Ltd. is a South Korean company specializing in the production, processing, and sale of frozen, chilled, and retorted food products. Founded in 1993 and headquartered in Yongin, the company offers a diverse range of meat products, including chicken and beef items, aimed at both home and business consumers. Notable offerings include Ginseng chicken stew, Mung bean chicken stew, Premium Samgyetang, boneless chicken tender, and Maniker popcorn chicken. Maniker F&G is also involved in exporting its products to the United States, emphasizing a commitment to providing delicious and safe food options through advanced meat processing technology and continuous innovation.